Jazz Pharmaceuticals announces FDA approval of Xywav oral solution for idiopathic hypersomnia in adults
Jazz Pharmaceuticals plc announced that the FDA approved Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of idiopathic hypersomnia in adults. The company plans… read more.
